Intralesional Bevacizumab Injection on Primary Pterygium

Sponsor
Khon Kaen University
Study ID
NCT01380678
Phase
PHASE3
Status
Unknown

Conditions

  • Inflammation
  • Pterygium

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Intralesional injection of bevacizumab — DRUG
    single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
  • Topical antihistamine and vasoconstrictor — DRUG
    combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%

Study Details

The purpose of this study is to evaluate that intralesional injection of bevacizumab on primary pterygium can reduce the corneal pterygium area, inflammation, redness and other symptoms.

Key Dates

First listed
Jun 27, 2011
Start date
Jan 31, 2009
Status verified
Jul 2010
Primary completion
Dec 31, 2012
Completion
Dec 31, 2012

Study Design

Enrollment
206 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: bevacizumab
    intralesional bevacizumab injection
  • Active Comparator: Topical antihistamine and vasoconstrictor
    combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%

Primary Outcome Measure

percentage of corneal pterygium area [ Time Frame: 3 years ]

Central Contacts

Related Studies